Development and preclinical evaluation of virus‐like particle vaccine against COVID‐19 infection
Allergy2021Vol. 77(1), pp. 258–270
Citations Over TimeTop 10% of 2021 papers
İsmail Yılmaz, Emre Mert İpekoğlu, Artun Bulbul, Nilsu Turay, Muzaffer Yıldırım, İrem Evcili, Naz Surucu Yilmaz, Nese Guvencli, Yusuf Aydın, Bilgi Gungor, Berfu Saraydar, Asli Gulce Bartan, Bilgehan İbibik, Tugce Bildik, İlayda Baydemir, Hatice Asena Sanli, Başak Kayaoğlu, Yasemin Ceylan, Tugce Canavar Yildirim, Irem Abras, İhsan Cihan Ayanoğlu, Sefa Burak Çam, Eda Çiftci Dede, Merve Gizer, Osman Erganiş, Fahriye Saraç, Serdar Uzar, Hakan Enül, Cumhur Adıay, Gamze Aykut, Hivda Ülbeği Polat, Ismail Selim Yildirim, Şaban Teki̇n, Gülay Korukluoğlu, Hasan E. Zeytin, Petek Korkusuz, İhsan Gürsel, Mayda Gürsel
Abstract
These data suggest that VLPs expressing all four structural protein antigens of SARS-CoV-2 are immunogenic and can protect animals from developing COVID-19 infection following vaccination.
Related Papers
- An overview of scientific and regulatory issues for the immunogenicity of biological products.(2003)
- → Immunogenicity of Therapeutic Proteins(2010)29 cited
- → Guidance on Immunogenicity Assessment of Biologically Derived Therapeutic Proteins: A European Perspective(2011)4 cited
- [An experimental study of the immunogenicity of Pseudomonas aeruginosa vaccines].(1976)
- → Immunogenicity(2015)